Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG known ✓ | Q16739 | 3/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 18/20 | 1.00 |
| ▸ | GBA1 | P04062 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | MGAM | O43451 | 2/20 | 1.00 |
| ▸ | SI | P14410 | 2/20 | 1.00 |
| ▸ | AGL | P35573 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miglustat SCHEMBL7911410 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19627563 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL6821044 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL19075917 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7911243 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL7908063 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL23503067 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20577242 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20576705 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20769803 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5373 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260097008-A1 | ACETYL LEUCINE FOR USE IN TREATING NIEMANN-PICK DISEASE TYPE C | INTRABIO INC. | 2026-04-09 | — | — | US | claimed |
| US-12576076-B2 | Use of HSP70 as a regulator of enzymatic activity | Zevra Denmark A/S (DK) | 2026-03-17 | — | — | US | claimed |
| EP-4705485-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4706779-A2 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | Amicus Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705484-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS | Voyager Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260041744-A1 | Methods for Treating Pompe Disease | AMICUS THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | claimed |
| US-12533403-B2 | Peptide conjugated particles | NORTHWESTERN UNIVERSITY (US) | 2026-01-27 | — | — | US | claimed |
| EP-4673215-A1 | GBA1 AND GCS DUAL MODULATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-5476859-A | Inhibiting lentivirus by orally administering derivatives of 1,5-dideoxy-1,5-imino-D-glucitol | PARTIS RICHARD A (US) | 1995-12-19 | — | — | US | claimed |
| WO-1995006061-A1 | RETROVIRAL PROTEASE INHIBITORS AND COMBINATIONS THEREOF | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| EP-0367748-B1 | Novel antiviral compounds | SEARLE & CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5310745-A | Acylated derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, AIDS | G. D. SEARLE & CO. (US) | 1994-05-10 | — | — | US | claimed |
| US-5151519-A | PROCESS FOR THE PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G. D. SEARLE & CO. (US) | 1992-09-29 | — | — | US | claimed |
| WO-1991017145-A1 | PROCESS FOR PREPARATION OF 1,5-(ALKYLIMINO)-1,5-DIDEOXY-D-GLUCITOL AND DERIVATIVES THEREOF | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
| US-5003072-A | Viricides | G. D. SEARLE & CO. (US) | 1991-03-26 | — | — | US | claimed |
| US-4957926-A | ALKYLIMINO-DIDEOXY-GLUCITOL COMPOUND | MONSANTO COMPANY (US) | 1990-09-18 | — | — | US | claimed |
| EP-0378984-A2 | Use of N-butyl-deoxynojirimycin in the treatment of herpes | MONSANTO COMPANY (US) | 1990-07-25 | — | — | EP | claimed |
| EP-0367748-A2 | Novel antiviral compounds | G.D. SEARLE & COMPANY (US) | 1990-05-09 | — | — | EP | claimed |